Pacira BioSciences is strategically reshaping its operations, transitioning from a diversified medical technology firm to an innovation-focused biopharmaceutical entity. This strategic pivot, coupled with robust financial outcomes in the second quarter of 2026, underscores the company's commitment to advancing its pipeline and expanding market reach for key products. Significant progress in securing broader insurance coverage for EXPAREL and the divestiture of the iovera business are central to this transformation, positioning Pacira for sustained growth amidst evolving market dynamics.
Detailed Report on Pacira BioSciences' Performance and Outlook
On , Pacira BioSciences convened its second-quarter earnings call. Key participants included Frank Lee (Chief Executive Officer), Brendan Teehan (Chief Commercial Officer), and Shawn Cross (Chief Financial Officer), alongside other executive team members. The company announced total revenues of $192.4 million, a 6% increase from the prior year, primarily driven by volume growth across its product portfolio. EXPAREL net product sales reached $147.8 million, showing a 3% increase, while ZILRETTA net product sales grew by 4% to $32.6 million. iovera net product sales saw a notable 22% increase to $6.8 million, attributed to strategic commercial investments. Licensee sales from third-party bupivacaine liposome products surged to $3.2 million, a significant rise from $500,000 in Q2 2025.
The company achieved a GAAP net income of $4.7 million, or $0.12 per diluted share, a positive shift from a net loss in the same period last year. Adjusted EBITDA stood at $48.7 million. As of June 30, 2026, Pacira reported a strong cash and investments position of $251.0 million, expected to increase further by a $73.6 million payment from the iovera divestiture. Market access for EXPAREL expanded significantly, now covering 150 million lives, following a pivotal contract with UnitedHealthcare that provides separate reimbursement. Full-year revenue guidance was adjusted to $735 million to $760 million, reflecting the iovera divestiture, while EXPAREL sales guidance remained at $600 million to $620 million. Non-GAAP selling, general, and administrative (SG&A) expenses were revised downward to $310 million to $330 million.
Pacira’s pipeline is robust, with enrollment progressing in Part B of the Phase 2 ASCEND study for PCRX-201, and top-line data for Part A anticipated by the end of 2026. Phase 3 study results for ZILRETTA in shoulder osteoarthritis are also expected later this year, potentially leading to the first FDA-approved indication for this condition. Enrollment for the iovera spasticity study is complete, with results due by year-end. The company’s management emphasized that the iovera divestiture to Zimmer Biomet, completed on July 31st, allows Pacira to sharpen its focus on biopharmaceutical innovation while preserving participation in iovera's future success through potential milestone payments. CEO Frank Lee highlighted that EXPAREL's patent exclusivity is projected to extend into the 2040s, ensuring long-term revenue potential. Furthermore, LG Chem's regulatory filing for EXPAREL in South Korea marks an important step toward international expansion, with revenues expected to commence in 2027.
Pacira BioSciences' recent strategic maneuvers and positive financial results demonstrate a clear vision for its future as a biopharmaceutical innovator. By divesting non-core assets and aggressively expanding market access for its flagship product, EXPAREL, the company is effectively leveraging partnerships and clinical advancements to drive growth. The emphasis on outpatient settings and a robust pipeline promises sustained value creation. This approach serves as a compelling model for biopharmaceutical companies navigating complex healthcare landscapes, highlighting the importance of focused innovation and strategic collaborations to achieve long-term success and enhance shareholder value.
